Lonely At The Top? Not In OTC Sector As Bayer, GSK/Novartis Challenge J&J
This article was originally published in The Tan Sheet
Executive Summary
Bayer closes its acquisition of Merck & Co.’s consumer business, aiming to become the top OTC player and saying other consumer product acquisitions could follow. Glaxo and Novartis look to close their agreement to combine their OTC businesses in the first half of 2015.
You may also be interested in...
Taking GSK's Consumer Helm Gives McNamara View From Atop The OTC Space
Brian McNamara becomes GSK Consumer CEO after Emma Walmsley is named to succeed Andrew Witty in 2017 to run Glaxo.
Taking GSK's Consumer Helm Gives McNamara View From Atop The OTC Space
Brian McNamara becomes GSK Consumer CEO after Emma Walmsley is named to succeed Andrew Witty in 2017 to run Glaxo.
Sanofi Adds Consumer Brands, Grows Footprint With Boehringer Ingelheim Deal
BI international brands including Mucoangin cough suppressant and Dulcolax constipation treatment and US heartburn remedy Zantac would join Sanofi's consumer portfolio including US brands Allegra Allergy antihistamines and Nasacort Allergy 24HR nasal decongestant in the firm's proposed asset swap.